Novo Nordisk Launches Lower-Cost Wegovy Cash Option and Home Delivery
Novo Nordisk has launched a new cash-pay option for its weight-loss drug Wegovy, offering a monthly dose at $499 with home delivery. The move follows competitor Eli Lilly's lead to offer a similar $499 cash program for its weight-loss drug Zepbound. This price reduction aims to make the medication more accessible to patients who do not have coverage or are uninsured.
- The decision by Novo Nordisk and Eli Lilly to launch lower-cost cash options signals a significant shift in the GLP-1 market, where manufacturers are now prioritizing affordability alongside treatment efficacy.
- Will this new pricing strategy from Novo Nordisk increase demand for Wegovy among patients who previously opted for alternative weight loss treatments due to high costs?